Phaseline

Companies › Helsinn Healthcare

Helsinn Healthcare: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fosnetupitant
Neurokinin 1 receptor antagonist
TACR1Phase 2Nausea and Vomiting Chemotherapy-InducedOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06904235FosnetupitantPhase 2Nausea and Vomiting Chemotherapy-InducedOtherOct 2027

Targets

TACR1 (1)

Companies with the same targets

Vanda Pharmaceuticals Bayer

Companies built like this

Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.